Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 35.6% in the past six months compared with the industry’s decline of 12.3%. The stock has underperformed the sector and the S&P 500 ...

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for my updated look at REGN.

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is spearheading a study titled ...

Regeneron has demonstrated strong performance across crucial financial metrics, and we contend this is not fully captured in its current stock valuation, which renders it an attractive investment.

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 8.5% over the past three months. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s ...

Most readers would already know that Regeneron Pharmaceuticals' (NASDAQ:REGN) stock increased by 9.6% over the past three months. Given that the market rewards strong financials in the long-term ...

This was the stock's second consecutive day of losses.

While Regeneron stock has rallied by about 45% year-to-date, it still appears reasonably valued, ... What Has Driven Regeneron’s Performance In Recent Years?

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years.

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 1.4% over the past week. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s ...